Thetford Mines, Quebec – August 7, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it has signed a letter of intent (“LOI”) with the shareholders of Consultandgrow Inc. (the “Shareholders”) on August 6, 2019 for the purchase of all the shares of Consultandgrow Inc. (“Consultandgrow”).

Thetford Mines, Quebec – July 18, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the private placement previously announced in its press releases dated December 17, 2018 and March 21, 2019 has been completed with accredited investors totaling 21,500,000 Class A shares (“Common shares”) at a price of $0.15 per Common share for total gross proceeds of $3,225,000 (the “Private Placement”).

Thetford Mines, Quebec – June 26, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that Dr. Giuseppe D’Aprano is appointed to the Corporation’s management team as Chief Scientific Officer (CSO) as of June 26, 2019.

Thetford Mines, Quebec – February 18, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the transaction with Strides Pharma Canada inc. (“Strides”) previously announced in its press releases dated December 4, 2018 and February 1st, 2019, according to which Strides acquired 80% of the issued and outstanding shares of its subsidiary Pharmapar Inc. (“Pharmapar”) has been completed.

Thetford Mines, Quebec – February 1st, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce, as previously disclosed in its press release dated December 4, 2018, that it has entered into a share purchase agreement (the “Purchase Agreement”) with Strides Pharmaceuticals Canada Inc. (“Strides”) under which Strides agreed to acquire 80% of the issued and outstanding shares of Pharmapar Inc. (“Pharmapar”), a subsidiary of KDA specializing in the distribution of generic drugs, for four million Canadian dollars (CAN$4,000,000) (the “Sale Price”).

Thetford Mines, Quebec – December 4, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it has signed a letter of intent (“LOI”) with Strides Pharma Global Pte Ltd. (“Strides”) for the sales of a majority stake in Pharmapar Inc. (“Pharmapar”), a division of KDA

Thetford Mines, Quebec – July 3, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce that it has signed an agreement for the acquisition of 51% of CanNorth Medic Inc.

Thetford Mines, June 1st, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the United States.

Thetford Mines, March 9, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced today that it has accepted the resignation of its Chief Financial Officer, Mr. Bruno Dumais, effective immediately. Mr. Dumais is leaving the Corporation to pursue other interests. In the interim, Mr. Michael Kinley, Chairman of the Audit Committee, will assume theresponsibilities of Chief Financial Officer.